MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Home・Akcijų sąrašas・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

15.26 0.59

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

14.44

Max

15.42

Pagrindiniai rodikliai
By Trading Economics
Pajamos	227M
Pardavimai	139M
P/E Sektoriaus vid.	5.766 63.808
Pelno marža	163.843
Darbuotojai	1,796
EBITDA	1.3M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+30.72% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	2.6B
Ankstesnė atidarymo kaina	14.67
Ankstesnė uždarymo kaina	15.26

Naujienos nuotaikos

By Acuity

50%

162 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

14.24 / 14.78 Palaikymas ir pasipriešinimas

Hutchison China MediTech Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-16 23:26; UTC

Karštos akcijos

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

2026-04-16 20:41; UTC

Pagrindinės rinkos jėgos

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

2026-04-16 23:49; UTC

Rinkos pokalbiai

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

2026-04-16 23:45; UTC

Rinkos pokalbiai

Nikkei May Decline After Hitting Record High -- Market Talk

2026-04-16 23:33; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

2026-04-16 22:51; UTC

Rinkos pokalbiai

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

2026-04-16 22:08; UTC

Uždarbis

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

2026-04-16 22:06; UTC

Uždarbis

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

2026-04-16 22:06; UTC

Uždarbis

Lundin Mining: Pre-Announces Items Impacting 1Q Results

2026-04-16 22:06; UTC

Uždarbis

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

2026-04-16 22:06; UTC

Uždarbis

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

2026-04-16 22:06; UTC

Uždarbis

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

2026-04-16 20:50; UTC

Rinkos pokalbiai

Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2026-04-16 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-04-16 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-04-16 20:50; UTC

Rinkos pokalbiai

Uždarbis

Health Care Roundup: Market Talk

2026-04-16 20:49; UTC

Uždarbis

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

2026-04-16 20:43; UTC

Uždarbis

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

2026-04-16 20:40; UTC

Rinkos pokalbiai

Uždarbis

Global Equities Roundup: Market Talk

2026-04-16 20:40; UTC

Rinkos pokalbiai

Uždarbis

Netflix Says Engagement Quality Hits New High -- Market Talk

2026-04-16 20:30; UTC

Karštos akcijos

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

2026-04-16 20:25; UTC

Uždarbis

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

2026-04-16 20:23; UTC

Uždarbis

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

2026-04-16 20:19; UTC

Uždarbis

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

2026-04-16 20:17; UTC

Uždarbis

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

2026-04-16 20:17; UTC

Uždarbis

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

2026-04-16 20:16; UTC

Uždarbis

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

2026-04-16 20:16; UTC

Uždarbis

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

2026-04-16 20:16; UTC

Uždarbis

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

2026-04-16 20:16; UTC

Uždarbis

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Akcijų palyginimas

Kainos pokytis

Hutchison China MediTech Ltd ADR Prognozė

Kainos tikslas

By TipRanks

30.72% į viršų

12 mėnesių prognozė

Vidutinis 20 USD 30.72%

Aukščiausias 20 USD

Žemiausias 20 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Hutchison China MediTech Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių Hutchison China MediTech Ltd ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

14.24 / 14.78Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

162 / 348 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.